
Samsung Surprised Us With the S25 Edge's Camera, Rivaling the Top-Notch Ultra
And yet the new Samsung Galaxy S25 Edge includes a surprising 200 megapixel (MP) f/1.7 wide camera that shares the same specs as the one in Samsung's Galaxy S25 Ultra. In fact, you could argue that the 200MP camera alone justifies the Edge's $1,100 price, with the latest versions of Android and Gemini as added bonuses in a thin and light body. That same resolution on the S25 Ultra starts at $1,300.
So why did Samsung choose to include a top-tier feature in a phone that sits in the middle of the company's S25 lineup? People want a good camera they can take everywhere, and they'll pay for it.
Read more: CNET's Abrar Al-Heeti reviews the Galaxy S25 Edge.
Watch this: Galaxy S25 Edge Hands-On: Samsung's Super-Thin Phone Is Impressive
03:33
Most phones are cameras with phone features
The difference between phones in the same lineup often comes down what each model adds over the others.
The Galaxy S25 is a thoroughly capable phone that (to cherry pick specs) runs the latest software on a Snapdragon 8 Elite processor, packs a 4,000 mAh battery, has a 6.2-inch display and features the following array of cameras: 50MP wide-angle, 12MP ultra-wide, 10MP 3x telephoto and 12MP front camera. For 256GB of storage, it costs $860. The 128GB base model starts at $800, but I'm using the 256GB version to keep the storage consistent across all our examples.
The Galaxy S25 Plus shares all of those same features in a larger package, with a 6.7-inch screen and -- due to its roomier case -- a larger 4,900 mAh battery. For that you'll pay an extra $140 more than the S25 to get the 256GB config at $1,000.
Then you jump $300 for the $1,300 Galaxy S25 Ultra, which boasts several specs such as the aforementioned 200MP main camera, a 50MP ultra-wide camera, a second 50MP telephoto camera with 5x optical zoom, a slightly larger 6.9-inch screen and a 5,000 mAh battery.
The Galaxy S25 Ultra justifies its higher price with a large array of separate cameras.
James Martin/CNET
So where does the Galaxy S25 Edge slot into the lineup? For $1,100, it has the same 6.7-inch screen as the S25 Plus with an additional layer of protection (it's covered with Corning's Gorilla Glass Ceramic 2), the same Snapdragon 8 Elite processor, a smaller 3,900 mAh battery (to be expected in a thinner case) -- and that 200MP wide camera.
The Galaxy S25 Edge's 200MP camera is an unexpected feature.
Samsung/Screenshot by Jeff Carlson/CNET
Although the camera shares the same specs as the one in the S25 Ultra, it's not yet clear whether it's the same hardware. In Samsung's event video officially announcing the S25 Edge, the company described how it redesigned the camera housing to fit the 200MP camera. I'm assuming it's the same core hardware, just repackaged to fit a smaller form factor, but a direct photo comparison will be the real test.
Samsung redesigned the wide camera assembly to fit into the Galaxy S25 Edge's svelte frame.
Samsung/Screenshot by Jeff Carlson/CNET
Thin isn't enough on its own
By the name alone, the primary appeal of the S25 Edge is its thin design. The company's introductory video is full of schematics and computer-generated animations of all the phone's components slotting together into its svelte body. And thinness does have value -- just look at Apple's obsession with making everything thin and light over the years, including its own rumored iPhone 17 Air.
But thinness as a feature isn't additive enough (to make the obvious joke, it's literally reductive). Samsung could have easily included the 50MP wide camera used on the S25 and S25 Plus and focused solely on the phone's design to set it apart. By including the top-end 200MP camera from the series' most expensive and premium phone, though, it hits a sweet spot where a customer thinks, "I'm getting a super thin version of the S25 but with the camera of the $1,300 S25 Ultra."
The thin profile of the Galaxy S25 Edge is absolutely appealing.
Carly Marsh/CNET
Decent zoom is still possible, even without a telephoto camera
The other thing that sets the S25 Edge apart is the fact that it does not include a dedicated telephoto camera. Every other S25 model includes at least one telephoto camera to zoom in on distant subjects.
That extra reach is usually the dividing line between "consumer" and "pro" models. For example, the Pixel 9 and 9A and iPhone 16 and 16E all include wide-angle and ultra-wide cameras, but no telephoto. People regularly zoom in when taking photos, so Google and Apple pitch higher-quality optical zoom as a premium feature at the higher price levels of the pro models.
But by including the 200MP camera on the S25 Edge, Samsung can still claim a 2x "optical quality" zoom. Technically that's a crop into the middle of the sensor, but the high megapixel count means there's still plenty of resolution to get quality images. You can still zoom at farther ranges, but you're leaning heavily on image processing to enhance the digitally-zoomed image.
Even at 10x digital zoom, the wide camera in the Galaxy S25 Edge performs well.
Abrar Al-Heeti/CNET
(An important aside about resolution: Keep in mind you're not always capturing images at 200MP resolution. The default resolution is a pixel-binned 12MP, where the camera groups pixels together on the sensor to act as a larger pixel that gathers more light. So at that resolution, the S25 Edge is likely using AI upscaling to zoom. But at the 50MP and 200MP resolution settings, the 2x zoom is more likely to be a straight crop from what the sensor is recording.)
This also reinforces the fact that phone photography is increasingly buttressed by real-time, AI-supported image processing. Shooting at the full 200MP resolution involves considerable processing to enhance details recorded by such a physically small image sensor. Even with pro phones, I regularly see people use pinch-to-zoom instead of switching among the better quality preset optical options. (Android Authority surveyed its readers and found that about 27% of respondents zoom freely versus sticking to preset zoom levels.)
Will customers specifically buy the S25 Edge because of its camera features? Not entirely, but touting the 200MP camera prominently along with the new thin design gives them extra incentive to choose it.
Be sure to check out Abrar Al-Heeti's photos from her first 24 hours with the Edge. To see more of what the 200MP can do, see CNET Managing Editor Patrick Holland's Galaxy S25 Ultra review, as well as Andrew Lanxon's images pitting the S25 Ultra head-to-head against the iPhone 16 Pro.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
o9 Introduces Li Auto's Integrated Planning Capabilities
Li Auto Inc. (NASDAQ:LI) is among the 12 Best EV Charging Stocks to Buy According to Hedge Funds. o9 announced the complete implementation of its Integrated Business Planning and Supply Planning capabilities at Li Auto Inc. (NASDAQ:LI), accomplishing a significant digital transformation milestone in less than a year. The collaboration began in late 2023 and achieved its first success within three months, with the implementation of Sales and Operations Planning technology. michael-fousert-YhXlYJYlr3c-unsplash Li Auto Inc. (NASDAQ:LI), a fast-expanding electric vehicle manufacturer in China, is among the first companies in the industry to utilize o9's Digital Brain platform for integrated end-to-end planning. It is among the Best EV Stocks. The collaboration yielded eight unique solutions, including a procurement-centered supply network, automatic BOM-to-SKU conversion, and integration with Feishu for real-time communication. According to Li Auto Inc. (NASDAQ:LI)'s IT Product Director Dongxin Wan, the solutions improve the business's flexibility and decision-making throughout its supply chain. Chakri Gottemukkala, the CEO of o9, acknowledged this collaboration as a standard in the digital transformation initiatives of the AI-powered EV market. While we acknowledge the potential of LI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
HD Hyundai, H-Line Shipping to develop AI-powered autonomous ship technology
HD Hyundai has entered a memorandum of understanding (MoU) with H-Line Shipping to co-develop AI-based autonomous and eco-friendly ship technology. The initiative aims to integrate AI into various aspects of ship operations to enhance efficiency, safety, and environmental sustainability. This collaboration will focus on advancements in autonomous navigation, engine automation, optimal route planning, and cargo transport efficiency. The MoU was signed at the HD Hyundai Global R&D Centre in Pangyo, bringing together executives from both companies. This agreement involves HD Korea Shipbuilding & Offshore Engineering (HD KSOE), HD Hyundai Marine Solution, Avikus, apart from H-Line Shipping. It outlines a joint development project that will see the integration of Avikus' autonomous navigation solution HiNAS, HD Hyundai Marine Solution's optimal routing solution OceanWise, and HD KSOE's AI-based cargo management system AI-CHS. HD Hyundai will manage the integration and implementation of the technology, while H-Line Shipping will contribute an LNG carrier for the sea trials and verification of the technology. The goal is to reduce fuel consumption and operational costs while increasing the safety and longevity of vessels. H-Line Shipping COO Ho-Dong Seo said: 'Technology that transports cargo via the most optimal routes using AI is a critical factor determining a shipping company's competitiveness. 'We expect this collaboration further to enhance the efficiency and safety of our fleet operations.' HD Hyundai and H-Line Shipping are positioning themselves to gain a competitive edge by developing solutions that address the entire ship lifecycle, from design and construction to operation and maintenance. This partnership aims to meet the growing demand for AI applications in shipping and the stringent environmental regulations set by the International Maritime Organisation (IMO). HD KSOE CTO Kwang-Pil Chang said: 'This partnership is the starting point for AI-based digital innovation that transcends the boundaries between shipbuilding and shipping. It will serve as an important milestone in setting the standard for the eco-friendly ships of the future.' In addition to this MOU, HD Hyundai has also recently signed an agreement with Cochin Shipyard Limited (CSL) in India to collaborate on shipbuilding. This partnership will focus on design and procurement support, technical collaboration for productivity and quality, and workforce training, with the potential for new shipbuilding orders both in India and abroad. "HD Hyundai, H-Line Shipping to develop AI-powered autonomous ship technology" was originally created and published by Ship Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Takeda Pharmaceutical Co Ltd (TKPHF) Q1 2026 Earnings Call Highlights: Navigating Challenges ...
Revenue: JPY1.1 trillion, a decrease of 8.4% or 3.7% at constant exchange rates (CER). Cooperating Profit: JPY321.8 billion, a decrease of 15.8% at actual FX or 11.9% at CER. Reported Operating Profit: JPY184.6 billion, an increase of 11%. EPS: JPY151 (KPS) and JPY79 (reported EPS). Adjusted Free Cash Flow: JPY190.1 billion. Growth and Launch Products Revenue: 50% of total revenue, grew 5% at CER. GI Segment Growth: 4.9% at CER. Debt Maturity: Average annual maturity approximately JPY220 billion over the next 3 years. Warning! GuruFocus has detected 5 Warning Signs with TKPHF. Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Takeda Pharmaceutical Co Ltd (TKPHF) reported positive results from two pivotal phase 3 studies of Oparoxin, which met all primary and secondary endpoints, indicating potential for a new standard of care in narcolepsy type 1. The company's late-stage pipeline is progressing rapidly, with plans to file for US approval of Oparoxin later this year and regional filings to follow. Takeda's growth and launch products, which represent 50% of revenue, grew by 5% at constant exchange rates in Q1, indicating strong performance in key areas. The company executed leveraged neutral bond issuances to streamline its debt maturity profile, securing favorable terms due to high demand. Takeda's plasma-derived therapies continue to expand, with new approvals in Japan and the US, enhancing their market presence. Negative Points Takeda Pharmaceutical Co Ltd (TKPHF) experienced an 8.4% decrease in revenue in Q1, primarily due to the impact of generic erosion on key products. The company's cooperating profit decreased by 15.8% at actual FX, reflecting challenges in maintaining profitability amidst competitive pressures. Intensified competition in the inflammatory bowel disease market led to a slower growth rate in the gastrointestinal segment. The impact of foreign exchange rates was a headwind this quarter, affecting revenue and profit margins. Some key products, including IG, Etivio, and Kenga, showed weaker performance in Q1, raising concerns about their recovery in subsequent quarters. Q & A Highlights Q: The sales of products like Etivio, IG, and Kenga were relatively weak in Q1. Do you expect a recovery for these products in the second quarter? Additionally, what benefits can we expect from the new molecule entering the pipeline after 861 and 360? A: Christophe Weber, CEO, responded that the first quarter was soft and does not reflect the underlying dynamics of their products, which is why they have not changed their guidance for the year. Andrew Plump, President of R&D, added that they expect the performance of these products to improve as market access expands, particularly for NTVO in the US. Regarding the new molecule, it is expected to provide additional benefits and advantages, but specific details were not disclosed. Q: Can you provide more details on the impact of generic erosion on your financial results and how you plan to mitigate this in the future? A: Milano Furuta, CFO, explained that the loss of exclusivity, particularly for high-margin products like Byance, significantly impacted Q1 results. However, they anticipate this impact to moderate in future quarters as the generic supply situation stabilizes and new product launches gain traction. Q: What are the expectations for the Ovipraxin launch, and how does it fit into Takeda's overall strategy? A: Andrew Plump, President of R&D, highlighted that Ovipraxin has shown promising results in phase 3 trials for narcolepsy type 1 and is on track to be a first-in-class treatment. The launch is expected to establish a new standard of care and contribute significantly to Takeda's growth strategy by addressing unmet medical needs. Q: How is Takeda managing its debt profile, and what are the plans for future refinancing? A: Milano Furuta, CFO, stated that Takeda executed leveraged neutral bond issuances to streamline its debt maturity profile. The company has managed to secure favorable terms due to high demand for its bonds and plans to maintain a manageable average annual maturity over the next three years. Q: Could you elaborate on the strategic importance of the late-stage pipeline and its potential impact on Takeda's long-term growth? A: Andrew Plump, President of R&D, emphasized that the late-stage pipeline, including programs like Zazositinib and Rusvertide, has the potential to deliver transformative benefits to patients. These programs are expected to contribute significantly to Takeda's long-term growth by expanding treatment options and addressing significant unmet needs. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. 登入存取你的投資組合